Form 4: Enliven Therapeutics COO Anish Patel Sells Shares Under 10b5-1 Trading Plan
SEC Form 4
Anish Patel, COO of Enliven Therapeutics, sold shares of common stock on April 7, 2025, under a pre-arranged 10b5-1 trading plan.
Summary
- Anish Patel, the Chief Operating Officer of Enliven Therapeutics, sold shares of the company's common stock on April 7, 2025.
- The sales were executed under a Rule 10b5-1 trading plan adopted on September 30, 2024.
- A total of 6,667 shares were sold in multiple transactions at varying prices.
- The weighted average sale prices ranged from $17.8087 to $19.2721 per share.
- Following the reported transactions, Patel indirectly owns 316,643 shares through The Patel / Dong Family Trust.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting the sale of shares by a company executive. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider trading activity. It is common for executives to use 10b5-1 trading plans to sell shares over time to avoid accusations of trading on inside information.
Stakeholder Impact
- The sale of shares by an executive could be perceived negatively by some shareholders, but the existence of a 10b5-1 trading plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| August 24, 2017 | Date of The Patel / Dong Family Trust |
| September 30, 2024 | Date of adoption of Rule 10b5-1 trading plan |
| April 07, 2025 | Date of the reported transactions |
| April 09, 2025 | Date of signature of the Form 4 filing |
Keywords
Enliven Therapeutics, Anish Patel, ELVN, Form 4, Share Sale, 10b5-1 Trading Plan, COO, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.